Investing
Cathie Wood's ARK Invest Sells Over 840,000 Shares of Seres Therapeutics

Published:
One of the ARK Invest exchange-traded funds run by ETF star Cathie Wood sold over 840,000 shares of Seres Therapeutics Inc. (NASDAQ: MCRB) shares on Monday, as the price of this ETF was up nearly 1% in Monday’s session. The fund is up significantly in the past year.
ARK Innovation ETF (NYSEARCA: ARKK) sold 846,468 shares of Seres Therapeutics. At Monday’s closing price, this would have valued this sale at roughly $5.2 million. This is only a small fraction of the total holdings. This ETF is up 35% over the past 52 weeks.
Here are all the ARK Invest sales on Monday:
Fund | Ticker | Name | Shares |
---|---|---|---|
ARKF | 6060HK | ZHONGAN ONLINE P&C INSURANCE | 981,100 |
ARKF | 9923HK | YEAHKA | 297,200 |
ARKG | PSTI | PLURISTEM THERAPEUTICS | 10,518 |
ARKG | CLLS | CELLECTIS | 7,300 |
ARKG | RHHBY | ROCHE | 78,900 |
ARKK | MCRB | SERES THERAPEUTICS | 846,468 |
ARKK | IOVA | IOVANCE BIOTHERAPEUTICS | 71,749 |
ARKQ | ISRG | INTUITIVE SURGICAL | 1,700 |
ARKQ | NXPI | NXP SEMICONDUCTORS | 13,000 |
ARKQ | BABA | ALIBABA | 15,089 |
ARKQ | GOOG | ALPHABET | 4,808 |
ARKW | MELI | MERCADOLIBRE | 4,500 |
ARKW | SE | SEA | 34,049 |
Catherine Wood, the CEO and CIO of ARK Investment Management, is a minority and nonvoting shareholder of 24/7 Wall St.
After two decades of reviewing financial products I haven’t seen anything like this. Credit card companies are at war, handing out free rewards and benefits to win the best customers.
A good cash back card can be worth thousands of dollars a year in free money, not to mention other perks like travel, insurance, and access to fancy lounges.
Our top pick today pays up to 5% cash back, a $200 bonus on top, and $0 annual fee. Click here to apply before they stop offering rewards this generous.
Flywheel Publishing has partnered with CardRatings for our coverage of credit card products. Flywheel Publishing and CardRatings may receive a commission from card issuers.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.